News & Updates
Filter by Specialty:
Foetal risk low in LMWH-exposed women during pregnancy
Pregnant women with preconception venous thromboembolism (VTE) who have no exposure to any anticoagulant and those on low-molecular-weight heparin (LMWH) have the lowest risk of foetal adverse outcomes, reveals a study, which supports the recommendation of LMWH during pregnancy.
Foetal risk low in LMWH-exposed women during pregnancy
11 May 2022
Sotorasib demonstrates durable efficacy in KRASG12C-mutated NSCLC
The KRASG12C inhibitor sotorasib has demonstrated durable efficacy in patients with locally advanced or metastatic KRASG12C-mutated non-small-cell lung cancer (NSCLC), with 2-year overall survival (OS) reported in one-third of patients in the CodeBreaK 100 trial.
Sotorasib demonstrates durable efficacy in KRASG12C-mutated NSCLC
11 May 2022
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
10 May 2022
Musculoskeletal pain common in T2D but does not influence treatment goals
Musculoskeletal pain is a common coexisting symptom in patients with type 2 diabetes (T2D), with most patients having knee or lower back pain, a study reports. However, despite the major disability burden associated with these types of pain, it does not seem to get in the way of achieving treatment targets.
